Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

Historical Holders from Q4 2022 to Q3 2025

Symbol
ACRV on Nasdaq
CUSIP
004890109
Type / Class
Equity / Common Stock, par value $0.001 per share (the "Shares")
Shares outstanding
31.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
17.5M
Holdings value
$32.6M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
46
Number of buys
15
Number of sells
-30
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 6.8% $2.82M 2.12M Sands Capital Life Sciences Pulse Fund II, L.P. Jun 30, 2025
CITADEL ADVISORS LLC 5.5% +12% $3.12M $327K 1.72M +11.7% Kenneth Griffin Nov 14, 2025

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 17.5M $32.6M +$817K $1.81 46
2025 Q2 17.8M $21.2M -$10.3M $1.19 52
2025 Q1 22.5M $45.7M -$2.11M $2.03 60
2024 Q4 23.3M $140M -$971K $6.02 60
2024 Q3 23M $161M -$2.68M $7.00 51
2024 Q2 23.5M $136M +$47.4M $5.80 51
2024 Q1 15.2M $109M +$3.45M $7.15 45
2023 Q4 10.7K $52.5K $4.92 1
2023 Q3 15.1M $144M -$326K $9.56 43
2023 Q2 15.1M $196M -$1.15M $12.96 40
2023 Q1 15.2M $191M +$6.82M $12.69 39
2022 Q4 14.5M $166M +$165M $11.52 17